- Home
- TOPS vs DARE Comparison
TOPS vs DARE Comparison
Compare TOPS & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPS
- DARE
- Stock Information
- Founded
- TOPS 2000
- DARE 2015
- Country
- TOPS Greece
- DARE United States
- Employees
- TOPS N/A
- DARE N/A
- Industry
- TOPS Marine Transportation
- DARE Biotechnology: Pharmaceutical Preparations
- Sector
- TOPS Consumer Discretionary
- DARE Health Care
- Exchange
- TOPS Nasdaq
- DARE Nasdaq
- Market Cap
- TOPS 27.4M
- DARE 26.3M
- IPO Year
- TOPS 2004
- DARE N/A
- Fundamental
- Price
- TOPS $5.55
- DARE $2.40
- Analyst Decision
- TOPS
- DARE Strong Buy
- Analyst Count
- TOPS 0
- DARE 3
- Target Price
- TOPS N/A
- DARE $12.50
- AVG Volume (30 Days)
- TOPS 141.9K
- DARE 39.0K
- Earning Date
- TOPS 08-08-2025
- DARE 08-11-2025
- Dividend Yield
- TOPS N/A
- DARE N/A
- EPS Growth
- TOPS N/A
- DARE N/A
- EPS
- TOPS 1.09
- DARE N/A
- Revenue
- TOPS $86,127,000.00
- DARE $25,909.00
- Revenue This Year
- TOPS $9.90
- DARE $99,756.91
- Revenue Next Year
- TOPS N/A
- DARE $119.77
- P/E Ratio
- TOPS $5.41
- DARE N/A
- Revenue Growth
- TOPS 3.83
- DARE N/A
- 52 Week Low
- TOPS $5.00
- DARE $2.35
- 52 Week High
- TOPS $11.47
- DARE $4.60
- Technical
- Relative Strength Index (RSI)
- TOPS 47.12
- DARE 30.40
- Support Level
- TOPS $5.10
- DARE $2.35
- Resistance Level
- TOPS $5.74
- DARE $2.95
- Average True Range (ATR)
- TOPS 0.80
- DARE 0.11
- MACD
- TOPS -0.14
- DARE -0.05
- Stochastic Oscillator
- TOPS 18.78
- DARE 6.49
About TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco tanker vessels focusing on the transportation of crude oil, petroleum products (clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements.
About DARE Dare Bioscience Inc.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.